Weekly epirubicin plus lonidamine in advanced breast carcinoma

Cecilia Nisticò, Carlo Garufi, Michele Milella, Anna Maria D'Ottavio, Angela Vaccaro, Alessandra Fabi, Edmondo Terzoli

Research output: Contribution to journalArticlepeer-review

Abstract

Lonidamine has been demonstrated to potentiate the cytotoxic activity of several antineoplastic drugs, for example anthracyclines. Moreover, epirubicin is considered one of the most active drugs in advanced breast cancer, although optimal dose and schedule remains to be defined. In the present study we have treated 51 patients with advanced breast cancer with a combination of lonidamine (450 mg/day orally from day 1 throughout treatment) and epirubicin (25 mg/m2 IV) administered according to a weekly schedule for 24 weeks. Objective responses were observed in 29 out of 51 patients (57%; CR 16%, PR 41%). Liver metastases responded in eight out of 12 evaluable patients (67%). Average response duration was 12.4 months and median overall survival was 23 months (range 1-90+). Toxicity was negligible. The combination of weekly epirubicin and lonidamine is feasible and active in advanced breast cancer patients.

Original languageEnglish
Pages (from-to)233-237
Number of pages5
JournalBreast Cancer Research and Treatment
Volume56
Issue number3
Publication statusPublished - 1999

Keywords

  • Advanced breast cancer
  • Epirubicin
  • Lonidamine
  • Weekly schedule

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Weekly epirubicin plus lonidamine in advanced breast carcinoma'. Together they form a unique fingerprint.

Cite this